Helena Santos de Moura Lima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Helena Santos de Moura Lima has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Breno José Alencar Pires Barbosa
Universidade Federal de Pernambuco, Empresa Brasileira de Serviços Hospitalares, Hospital das Clínicas, Serviço de Neurologia, Recife PE, Brazil
3 shared publications - Aimê de Paula Santos
Universidade Federal de Pernambuco, Centro de Ciências Médicas, Recife PE, Brazil
2 shared publications - Jesus Manoel Bernardez Gandara
Real Hospital Português de Beneficência em Pernambuco, Recife PE, Brazil
2 shared publications - Letícia Klabinske Marques Monteiro
Universidade Federal de Pernambuco, Empresa Brasileira de Serviços Hospitalares, Hospital das Clínicas, Serviço de Neurologia, Recife PE, Brazil
2 shared publications - Luziany Carvalho Araújo
Universidade Federal de Pernambuco, Empresa Brasileira de Serviços Hospitalares, Hospital das Clínicas, Serviço de Radiologia, Recife PE, Brazil
2 shared publications - Rejane de Souza Macedo Campos
Hospital Israelita Albert Einstein, São Paulo SP, Brazil
2 shared publications
Latest Publications
- Open Access
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (08) , 001-005
A challenging case of Down syndrome regression disorder
Down syndrome regression disorder (DSRD) is a rare cause of neuropsychiatric regression observed in previously-healthy individuals with Down syndrome (DS). There have been reports of brain iron accumulation in the basal ganglia of patients with DS and DSRD, although the underlying etiology remains unclear. The current study aims to report, through detailed neuroimaging, laboratory tests, and clinical data findings, the case of a patient with DS who experienced a significant loss of abilities, accompanied by neuroimaging findings indicative of abnormal brain iron accumulation. While an extensive investigation with blood, cerebrospinal fluid (CSF), and genetic markers was unremarkable, magnetic resonance imaging (MRI) scans revealed abnormal iron deposition and calcifications in the globus pallidus. The abnormal iron accumulation in the basal ganglia of patients with DSRD could be a potential neuroimaging marker for this condition.
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (08) , 001-005
Open AccessA challenging case of Down syndrome regression disorder
Down syndrome regression disorder (DSRD) is a rare cause of neuropsychiatric regression observed in previously-healthy individuals with Down syndrome (DS). There have been reports of brain iron accumulation in the basal ganglia of patients with DS and DSRD, although the underlying etiology remains unclear. The current study aims to report, through detailed neuroimaging, laboratory tests, and clinical data findings, the case of a patient with DS who experienced a significant loss of abilities, accompanied by neuroimaging findings indicative of abnormal brain iron accumulation. While an extensive investigation with blood, cerebrospinal fluid (CSF), and genetic markers was unremarkable, magnetic resonance imaging (MRI) scans revealed abnormal iron deposition and calcifications in the globus pallidus. The abnormal iron accumulation in the basal ganglia of patients with DSRD could be a potential neuroimaging marker for this condition.
- Open Access
- 12 May 2026
- Vol. 84 (8) , 1-5
A challenging case of Down syndrome regression disorder.
Down syndrome regression disorder (DSRD) is a rare cause of neuropsychiatric regression observed in previously-healthy individuals with Down syndrome (DS). There have been reports of brain iron accumulation in the basal ganglia of patients with DS and DSRD, although the underlying etiology remains unclear. The current study aims to report, through detailed neuroimaging, laboratory tests, and clinical data findings, the case of a patient with DS who experienced a significant loss of abilities, accompanied by neuroimaging findings indicative of abnormal brain iron accumulation. While an extensive investigation with blood, cerebrospinal fluid (CSF), and genetic markers was unremarkable, magnetic resonance imaging (MRI) scans revealed abnormal iron deposition and calcifications in the globus pallidus. The abnormal iron accumulation in the basal ganglia of patients with DSRD could be a potential neuroimaging marker for this condition.
- 12 May 2026
- Vol. 84 (8) , 1-5
Open AccessA challenging case of Down syndrome regression disorder.
Down syndrome regression disorder (DSRD) is a rare cause of neuropsychiatric regression observed in previously-healthy individuals with Down syndrome (DS). There have been reports of brain iron accumulation in the basal ganglia of patients with DS and DSRD, although the underlying etiology remains unclear. The current study aims to report, through detailed neuroimaging, laboratory tests, and clinical data findings, the case of a patient with DS who experienced a significant loss of abilities, accompanied by neuroimaging findings indicative of abnormal brain iron accumulation. While an extensive investigation with blood, cerebrospinal fluid (CSF), and genetic markers was unremarkable, magnetic resonance imaging (MRI) scans revealed abnormal iron deposition and calcifications in the globus pallidus. The abnormal iron accumulation in the basal ganglia of patients with DSRD could be a potential neuroimaging marker for this condition.
- Open Access
- 11 December 2025
- Published by Universidade Federal de Pernambuco in Estudos Universitários
- Vol. 42 (1) , 1-42
Use of artificial intelligence in predicting cognitive decline and dementia: a systematic review
The use of Artificial Intelligence (AI) and Machine Learning (ML) has been applied in several studies to detect the conversion from mild cognitive impairment (MCI) to dementia. This study aims to identify challenges and effective methods for applying AI in predicting cognitive decline and dementia. A literature review was conducted by searching the PubMed database between May and July 2024, using predefined eligibility criteria. The analysis included 17 studies involving 12,183 participants (aged 50 to 85 years). The review included 17 articles published between 2015 and 2023, predominantly observational studies. The AI tools applied encompassed demographic and lifestyle data, imaging exams, cognitive tests, biomarkers, and physiological data. MCI was the most prevalent diagnosis among the studies, with a particular focus on the amnestic subtype. Nine studies investigated the conversion from MCI to some form of dementia; four analyzed the prediction of beta-amyloid positivity; three employed ML for diagnostic support in distinguishing controls from patients with different types of dementia; and one assessed the cognitive risk in an elderly population. Among the best-performing approaches identified, multimodal data strategies — especially those involving MRI imaging and sociodemographic information — stood out. Applications involving multimodal datasets, particularly those including MRI exams, improve the overall performance of ML models and are considered among the most effective approaches. Future research should focus on the diagnosis and prediction of less-studied dementias, such as frontotemporal dementia, through the use of AI. The integration of multimodal data, including demographic information, imaging exams, cognitive assessments, and biomarkers, should be encouraged.
- 11 December 2025
- Published by Universidade Federal de Pernambuco in Estudos Universitários
- Vol. 42 (1) , 1-42
Open AccessUse of artificial intelligence in predicting cognitive decline and dementia: a systematic review
The use of Artificial Intelligence (AI) and Machine Learning (ML) has been applied in several studies to detect the conversion from mild cognitive impairment (MCI) to dementia. This study aims to identify challenges and effective methods for applying AI in predicting cognitive decline and dementia. A literature review was conducted by searching the PubMed database between May and July 2024, using predefined eligibility criteria. The analysis included 17 studies involving 12,183 participants (aged 50 to 85 years). The review included 17 articles published between 2015 and 2023, predominantly observational studies. The AI tools applied encompassed demographic and lifestyle data, imaging exams, cognitive tests, biomarkers, and physiological data. MCI was the most prevalent diagnosis among the studies, with a particular focus on the amnestic subtype. Nine studies investigated the conversion from MCI to some form of dementia; four analyzed the prediction of beta-amyloid positivity; three employed ML for diagnostic support in distinguishing controls from patients with different types of dementia; and one assessed the cognitive risk in an elderly population. Among the best-performing approaches identified, multimodal data strategies — especially those involving MRI imaging and sociodemographic information — stood out. Applications involving multimodal datasets, particularly those including MRI exams, improve the overall performance of ML models and are considered among the most effective approaches. Future research should focus on the diagnosis and prediction of less-studied dementias, such as frontotemporal dementia, through the use of AI. The integration of multimodal data, including demographic information, imaging exams, cognitive assessments, and biomarkers, should be encouraged.